


European Journal of Medicinal Chemistry



journal homepage

Review article

Privileged scaffolds as MAO inhibitors: Retrospect and prospects





b Pharmocy Department, Banasthali Vidyapith, Banasthali, Tonk 304022, Rajasthan, India

ARTICLEINFO

Article history
Received 11 September 2017
Received in revised form
1 December 2017
Accepted 1 January 2018
Available online 4 January 2018

Keywords
MAO inhibitors
Privileged structures
MAO pharmacology
SAR of MAOIs
Therapeutic potential of MAO inhibitors
2-Pyrazolines
Coumarins
Natural compounds as MAO inhibitors
Patents on MAO inhibitors

ABSTRACT

This review aims to be a comprehensive, authoritative, critical, and readable review of general interest to the medicinal chemistry community because it focuses on the pharmacological, chemical, structural and computational aspects of diverse chemical categories as monoamine oxidase inhibitors (MAOIs). Monoamine oxidases (MAOs), namely MAO-A and MAO-B represent an enormously valuable class of neuronal enzymes embodying neurobiological origin and functions, serving as potential therapeutic target in neuronal pharmacotherapy, and hence we have coined the term "Neurozymes" which is being introduced for the first time ever. Nowadays, therapeutic attention on MAOIs engrosses two imperative categories; MAO-A inhibitors, in certain mental disorders such as depression and anxiety, and MAO-B inhibitors, in neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD). The use of MAOIs declined due to some potential side effects, food and drug interactions, and introduction of other classes of drugs. However, curiosity in MAOIs is reviving and the recent developments of new generation of highly selective and reversible MAOIs, have renewed the therapeutic prospective of these compounds. The initial section of the review emphasizes on the detailed classification, structural and binding characteristics, therapeutic potential, current status and future challenges of the privileged pharmacophores. However, the chemical prospective of privileged scaffolds such as; aliphatic and aromatic amines, amides, hydrazines, azoles, diazoles, tetrazoles, indoles, azines, diazines, xanthenes, tricyclics, benzopyrones, and more interestingly natural products, along with their conclusive SARs have been discussed in the later segment of review. The last segment of the article encompasses some patents granted in the field of MAOIs, in a simplistic way.

© 2018 Elsevier Masson SAS. All rights reserved.

Contents

1	Introduction	146
•	1.1 Structure and binding site analysis of MAOs	146
	12. MAO substrates and catalysis	148
		149
	1.3. Functions of MAOs	140
	1.4. Estimation of MAOs	453
2.	MAO pharmacology	151
	2.1 Monoamine oxidase inhibitors (MAOIs)	45 I
	2.2 Classification of MAOIs	451
	2.3. Therapeutic potential of MAOIs	154
	2.3.1 MAOIs in neuropharmacological disorders	155
	2.3.2. MAOIs in other diseases	156
	2.4. Side effects/ADRs associated with MAOIs and challenges to newer agents	157
	2.4. Side effects/ADRs associated with MAOIs and chanlenges to newer agents Privileged scaffolds as MAO inhibitors	157
3.	Privileged scaffolds as MAO inhibitors	151
	3.1. Aliphatic and aromatic amines	28

E-mail address.

(S.K. Saraf).

Corresponding author Division of Pharmaceutical Chemistry, Faculty of Pharmacy, Babu Banarasi Das Northern India Institute of Technology, BBD City, Faizabad Road, Chinhat, Lucknow 226028, UP, India.